Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhopressa for Corneal Clearing in Fuchs Dystrophy
NCT03971357Phase 3
Key facts
- Status
- Terminated
- Start
- Jul 2019
- Primary completion
- Aug 2021
- Countries
- 1
- Sponsor
- Price Vision Group
- Modality
- Small Molecules
- Drugs
- netarsudil
- Conditions
- Fuchs endothelial dystrophy (FED)
01
Overview
Phase 3, randomised, double-blind trial in Fuchs endothelial dystrophy (FED) comparing Netarsudil with Placebo (2 arms). Primary endpoint: Corneal Clearing After Endothelial Removal for Treatment of Fuchs Dystrophy at 6 weeks. Started Jul 2019; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Netarsudil
Netarsudil ophthalmic solution 0.02% daily
Placebo
Placebo eye drops daily
03
Endpoints
Primary
Corneal Clearing After Endothelial Removal for Treatment of Fuchs Dystrophy
Secondary
Corrected Distance Visual Acuity
Central Endothelial Cell Density
Beyond the preview
Go deeper on NCT03971357.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971357.